RecruitingNCT05007340

ILD-SARDs Registry and Biorepository

Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository


Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Enrollment

252 participants

Start Date

Aug 24, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a registry and tissue bank (biorepository) for people who have both interstitial lung disease (ILD) and a systemic autoimmune rheumatic disease (SARD). ILD causes scarring or inflammation in the lungs, and when it occurs alongside conditions like rheumatoid arthritis, lupus, or scleroderma, it can be particularly complex to treat. This registry will help researchers better understand these overlapping conditions and develop better treatments. You may be eligible if: - You are 18 years of age or older - You have been diagnosed with interstitial lung disease, confirmed by a chest CT scan - You have a defined systemic autoimmune rheumatic disease (SARD), undifferentiated connective tissue disease, or signs of autoimmunity even without a formal SARD diagnosis - You are willing and able to give informed consent and follow study procedures You may NOT be eligible if: - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood draws

Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.

OTHEROther biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)

If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.

OTHERClinical data collection

Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.

OTHERGenetic data/DNA/RNA

Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).


Locations(1)

RI-MUHC

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05007340


Related Trials